Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cho-h01
- Development stage
- Phase 2
- Lead developer
- Cho Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CHO-H01 is a glycoengineered monoclonal antibody targeting CD20, a surface marker specifically expressed on B cells. It is the world's first biobetter antibody with homogeneous, fully α2,6-sialylated biantennary glycan. The drug's mechanisms of action include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and induction of apoptosis. Compared to its non-glycoengineered parental form, CHO-H01 demonstrates increased binding affinity to Fc gamma receptor IIIa and significantly enhanced ADCC activity (by 30-50 fold) in preclinical studies. It also shows potent activity against B lymphoma cells resistant to rituximab. CHO-H01 is being developed for the treatment of various subtypes of non-Hodgkin lymphoma and is currently in Phase I/II clinical trials[1][2][3][5].
- Other names
- glyco-engineered anti-CD20 monoclonal antibodyglycoengineered biobetter antibody
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD20 (B-lymphocyte antigen CD20)C1Q (Complement C1q)
Beyond the preview
Go deeper on cho-h01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cho-h01.